Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HEALEY ALS Platform Trial

Trial Profile

HEALEY ALS Platform Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 May 2025 According to a Transposon Therapeutics media release, the TPN-101 has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial. Initiation of the TPN-101 regimen in the HEALEY ALS Platform Trial is expected in Q4 2025
  • 06 Jan 2025 According to a Calico media release, more regimens will become available soon, with the goal of adding approximately three regimens per year.
  • 10 Dec 2024 According to a Clene media release, Clene will meet with the FDA in early 2025 to review and finalize its statistical analysis plan for the EAP NfL biomarker analyses.Survival Pharmacometric Modeling: Provide analyses of NfL and related disease-specific biomarkers linked to clinical survival benefit and clinical changes from the Phase 2 trial data

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top